Acebilustat
Acebilustat (CTX-4430, EP-501) is a potent and selective leukotriene A4 hydrolase (LTA4H) inhibitor with IC50 of 64 nM for inhibition of LTB4 production in human whole blood; a new once‐daily oral antiinflammatory drug in development for treatment of cystic fibrosis (CF) and other diseases.Cystic Fibrosis, Phase 2 Clinical (In Vitro) :Acebilustat (CTX-4430) is a leukotriene A4 hydrolase inhibitor, which is safe and well tolerated in phase 1 trial. Acebilustat is an antiinflammatory drug in development for the treatment of CF and other diseases. It is a potent inhibitor of the enzyme leukotriene A4 hydrolase (LTA4H), which catalyzes the rate-limiting step in the formation of leukotriene B4 (LTB4), a potent chemoattractant and activator of inflammatory immune cells including neutrophils.
Product Specifications
CAS Number
943764-99-6
Product Name Alternative
CTX-4430 | EP-501
Purity
>98% (HPLC)
Solubility
10 mM in DMSO; Methanol: ≥ 32 mg/mL
Smiles
O=C (O) C1=CC=C (CN2[C@] (C3) ([H]) CN (CC4=CC=C (OC5=CC=C (C6=NC=CO6) C=C5) C=C4) [C@]3 ([H]) C2) C=C1
Molecular Formula
C29H27N3O4
Molecular Weight
481.5424
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Benzoic acid, 4-[[ (1S,4S) -5-[[4-[4- (2-oxazolyl) phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]-
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
